TW's Take: BARDA is a great endorsement for the technology. TFFP's balance sheet issues notwithstanding, the value here for the tech is insane.
Partnership funded by BARDA and other US government agencies
TFF formulation may provide flexibility of delivery and improve...
TW's Take: more proof of the power of the TFF platform. If only funding were in place, the value here is crazy cheap.
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza...
This week the market got the flu. Unfortunately, so did I.
Perhaps the best way to deal with a weak market is from the sick bed...stock price movement didn't seem like the biggest problem I had at the time. Instead...
TW's Take: giving the opening keynote address is a big honor and demonstrates just how exciting ANIX's CAR-T program is. The therapy continues to fly beneath the radar screen but not for much longer.
SAN JOSE, Calif., Sept. 3, 2024 /PRNewswire/ -- Anixa...
TW's Take: NVNO is making all the preparations for a big launch next year. Exciting times ahead for the company.
MedTech Marketing Leader with Significant New Product Launch Experience for Cardiovascular Devices
Key Addition to Commercial Team as Company Begins Planning...
This weekend I'm heading up to New York to watch the US Open. It's my first time going and I'm super excited. Albeit a little less so when Carlos Alcaraz flamed out of the event in the second round....
The dramatic turnaround in the market after the swoon in early August continued this week with the indexes all making strong moves higher. For the S&P 500, we are within spitting distance of all-time highs.
Driving stocks higher are the...
In the last two weeks we have seen markets collapse, only to rapidly recover lost ground. The spike in the volatility index was indicative of a coming crash. Instead, however, we got by far the fastest drop back to...
TW's Take: the company is doing everything right as they march forward towards approval.
VenoValve PMA Approval Application Process Consists of the Submission of 5 Modules to the FDA
4 Modules Have Now Been Submitted, Reviewed, and Approved by the FDA
Company...
Rodney Dangerfield made a fortune out of playing the role of an underappreciated comedian. Famous for the line, "I get no respect," Dangerfield's skits went beyond self-deprecating. Thankfully he chose to be a comedian as he got well paid...
TW's Take: a great update as TFF-TAC continues to demonstrate outstanding efficacy and safety. The drug has an increasingly high likelihood of being a blockbuster. I expect they will be able to partner the program off sometime in 2025,...
If you watch Texas Hold 'Em on TV, it's exciting. Lots of great hands, crazy bluffs and big pots. The game is exciting and makes you want to go to Vegas. However, believe it or not, reality doesn't exactly...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I managed to catch up with Amit Kumar, the CEO of Anixa. He provided...
ATLANTA, July 30, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) announces it has acquired the Environmental Waste Operations Center (EWOC) near Oak Ridge, Tennessee. The EWOC facility has been leased by the Company for...
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways
BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing...
TW's Take: nice industry recognition for what is looking, in the early stages, like a very interesting therapy with great potential for Anixa.
SAN JOSE, Calif., July 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused...
Small cap stocks continue to put in a great rally, one that was long overdue. This past week saw the Russell 2000 gain 3% while the S&P 500 lost 1%. The pendulum is finally swinging back in the direction...
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics
BOCA RATON, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology...
TW's Take: this is a very positive outcome for someone in the lowest dose cohort of this trial. While we need to see this across more patients, if this continues, the therapy could be on track for blockbuster status...
TW's Take: nice to see they are optimistic enough to increase the burn and his joining is validation. Where are the partners?
LOS GATOS, Calif.--(BUSINESS WIRE)-- Atomera Incorporated (NASDAQ:ATOM), a semiconductor materials and technology licensing company, today announced the appointment of Shawn Thomas as...
An interesting week in the markets as the shooting of Donald Trump's ear caused, at least at first, a continuation of the rally we had been seeing in small cap stocks. By the close Tuesday, the R2K had rallied...
TW's Take: this is a display of confidence in the upcoming results from both programs. I expect to see positive CAR-T data in particular over the coming months.
SAN JOSE, Calif., July 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:...
What a week in the TW universe. It started out slow with more of the consistent, across the board selling that has come to be the norm for 2024. Then, seemingly out of the blue, a minor rally on...
With the first half of 2024 now in the record books, it was certainly one that microcap investors would love to forget. The large indexes, led by the Magnificent Seven which put on a fireworks display, closed on a...
TW's Take: seems like exciting news but need to get more understanding of the levels of performance increase which would need to be significantly high to drive adoption. Continue to believe in the future here but taking forever.
Ultra-Thin MST-Enabled...
This week I'm starting the newsletter with a discussion on INmune Bio (INMB). There are two reasons for this. Firstly, the company put out a Press Release on Thursday that I deem to be highly significant. We'll discuss that...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I have exciting news to announce to everyone. Starting July 1, I will be...
TW's Take: this is a very positive update confirming the endpoint's effectiveness and the trial design. We are nearing the end of enrollment, with data to come approximately six months later. Very exciting times for INMB.
The planned interim...
TW's Take: very positive update as they remain on track and on budget for getting their pivotal trial approved and launched later in 2024.
FDA Provided Constructive Feedback to Help Guide Next Steps in TFF TAC Clinical Development
Company...
TW's Take: enrollment is going much better now as it appears that the safety profile is excellent while there are initial signs of efficacy. Looking forward to seeing some clinical data around efficacy later this year, which, if positive,...
This week the action in IN8bio (INAB) pretty much sums up the last couple years for growth focused micro-caps. The stock made a nice move into data being presented at the European Hematology Association. The stock had moved from...
TW's Take: more outstanding data from INAB. The program is expensive but appears to be successful in keeping patients alive.
100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid...
TW's Take: this is a great opportunity for PESI and we look forward to seeing what kind of revenues can be generated by this product over the coming years...could be quite substantial.
Selects ProcessBarron for fabrication and assembly of...
This week we had a chance to interview Dr. Harlan Weisman, the CEO of TFF Pharma (TFFP). Dr. Weisman related the current travails at TFF to his experience at Centocor, a biotech company which he helped get off the...
Despite turning the company around operationally, shares of TFF Pharma (TFFP) have fallen dramatically since Dr. Harlan Weisman took over the reins as CEO in Oct. of 2022. It is our belief that the company's internal products have more...
TW's Take: good data as INAB continues to show efficacy in a very difficult disease.
92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp...
For pre-revenue companies, times are tough. Funding remains incredibly hard to come by and, for those who display any weakness, the markets are simply brutal. After suffering through what some have called the longest bear market in the history...
TW's Take: more positive execution on orders that prove the technology while helping keep the burn low while we await the big mobile and auto orders that could come in the second half of 2024.
New Award Invests in High...
In San Diego, one might think that June would be one of the best months for weather. You would be partially right. Almost every morning in that part of the world, the heat of the Central Valley brings in...
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to...
TW's Take: while this won't result in revenue any time soon, it's further proof of the technology. As TAC moves into its pivotal trial, partners should be more interested due to the validation of thin film freezing. Having DARPA...
TW's Take: this funding, while surprising to the market, should enable them to rapidly develop their PFAS solution; a very timely area of focus.
ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (Nasdaq: PESI) (“Perma-Fix” or the...
TW's Take: Further proof of the potential for the Thin Film Freezing platform technology. Another shot on goal and this one paid for through a grant. The value inherent in the stock right now is borderline insane.
FORT WORTH, Texas,...
TW's Take: This therapy has the potential to be worth billions of dollars to Anixa and we could be getting results later this year...
Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid...
This weeks newsletter comes from the Valley of the Sun. It's hot already in Phoenix, where they are currently in a stretch of 100+ days. The only thing hotter could be the S&P, which is on a tear.
Adding to...
TW's Take: more outstanding results from TAC as this drug has all the makings of being a best-in-class blockbuster within a couple years. Now, how to finance that future success???
Patient Enrollment Has Accelerated with Now 10 Patients Enrolled...
In March, I wrote the following..
Markets are nothing if not forward looking. Typically, the start discounting events six months in advance. With election day being November 5th, I'm going on record and predicting the stock market starts sputtering in...
TW's Take: a decent quarter but the stage is set for a great last three months of 2024.
ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update...
TW's Take: strong execution sets the stage for continued growth in the business and in the stock price.
Double-Digit Growth in Gross Profit Resulting from Business Expansion and Efficiency Gains
Significant New Business Wins and Pipeline Growth Reflect Company’s...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
A few things to discuss today...
Aaron Fletcher of BIOS Partners will be joining us...
TW's Take: quite a positive step as partnering with the renowned Cleveland Clinic on additional vaccines speaks to how well the current trials are proceeding.
– Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines –
SAN JOSE,...
Last week's topic of conversation was INmune Bio (INMB) and how they had pulled off a very high quality financing. It had solid investors led by the management team and committed to staying with the stock for the long-term....
TW's Take: Needed capital gives TFF the runway to get through some big milestones including FDA go ahead to launch pivotal trials, which should be a key value inflection point. Crazy cheap, weak balance sheet and investor base.
FORT WORTH,...
TW's Take: mind-blowing results from an admittedly small "n". I am not aware of any other clinical trial in AD that has had one patient stable after more than a year. In their phase 1 trial, XPro is 2...
TW's Take: more compelling evidence supporting TFF TAC. Valuation here remains crazy low. When will partners care?
Data Now Available on Company Website Following 8-K Filing
Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only...
TW's Take: enrollment is going great and we should see some clinical data over the summer. This program has the chance to catch the market by surprise as it's overlooked but has multi-billion dollar potential. Exciting year for INMB.
Boca...
Until they mature and hit profitability, small-cap growth companies rely on financings to fund their operations. Sometimes that money is easy to come by and sometimes it simply isn't. This is most likely the one key fact to consider...
TW's Take: this financing is a high-quality deal with only one investor who was limited to $9.7M to stay below 5% of the company. INmune is now primed for a push into data with nothing holding them back.
Boca Raton,...
TW's Take: QRHC is just beginning a strong, organic growth phase that should propel this stock to new highs.
Additional Significant Client Win to Start Off the Second Quarter
Financial Results and Earnings Conference Call to be held at...
TW's Take: INmune is getting their ducks in a row for a large phase 3 trial, which we hope to see starting near the end of 2025. This is an exciting time for INMB as the next year is...
TW's Take: this approval should help accelerate patient enrolling in this program.
Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population.
Dr. Yashushi Goto a leading...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
This morning, INmune Bio (INMB) announced a small financing. I believe this financing has...
TW's Take: this provides the capital to get the company through top-line AD data. I suspect the shorts are going to be very worried about that.
Boca Raton, Florida, April 22, 2024 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage...
That explosion you heard last week was Spectra7 (SPVNF) imploding. After putting up close to a zero in revenue in Q4, they only slightly exceeded that mark in Q1. The stock didn't take it nearly as well this time...
TW's Take: organic growth is strong at QRHC and the company remains very reasonably priced for their potential.
Quest’s Turnkey Waste, Recycling, and Food Waste Diversion Solutions to be Implemented Across UNFI’s U.S. and Canada Facilities
THE COLONY, Texas, April 18, 2024...
TW's Take: adding Dr. Juneja to the board should really help drive awareness of Anixa's programs.
SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced...
TW's Take: data from this trial exceeds all expectations.
IRVINE, CA / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that additional...
TW's Take: TFF-TAC continues to have the data to support potential blockbuster status. Once the balance sheet issues are resolved, the value here will be recognized.
New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence...
One recurring theme I've stressed in this newsletter is concern around the Federal deficit, a looming disaster that seemingly is ignored by most politicians. Our debt level is the highest ever with deficits only projected to grow. With the...
TW's Take: this is a solid hire as his experience dovetails nicely into getting the VenoValve acquired by a larger device company post approval.
Appointment bolsters Company’s transition from being a clinical stage to a commercial entity planning for the...
TW's Take: outstanding data sets the stage for potential partnering of INB03.
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer
Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) --...
Greetings from Sicily, a land of great beauty, great food and great wine. It's a lovely time of year to visit here, neither too hot nor too crowded. We've toured the city streets and climbed the hills to visit...
TW's Take: Great news for MOVE as they needed cash and this is a nice endorsement by insiders and a quality strategic.
Financing included a strategic seed investment by a tier-1 multi-billion dollar medical device company and participation from...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Greetings from Barcelona. As I'm traveling, I'm not putting out a newsletter this week...
TW's Take: further endorsement of the value of TAC. I believe partners will be highly interested in this program going forward as the data is compelling.
Oral Presentation to Present Updated Data from Phase 2 Trial Demonstrating Successful Transition...
Markets had another strong week as the bull market continues apace. I continue to be constructive on micro-caps as the relative disparity remains far larger than historical norms. As long as the markets expect rate cuts this year, opportunities...
TW's Take: the balance sheet continues to be the biggest risk to TFFP. Once that's squared away, the stock should perform quite well.
FORT WORTH, March 20, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
This morning TFF Pharma came out with a press release discussing data from both...
TW's Take: very positive announcement in many ways. The data for both drugs is excellent with TAC surpassing even the highest expectations. If VORI can be partnered, the company will be very well positioned to have a blockbuster drug...
TW's Take: organic growth finally taking off. Well positioned for a big 2024.
New Business Wins, Client Renewals, Revenue Growth, and Pipeline Growth Reflect Accelerated Momentum Across Business
Completed Integrations of All Previously Announced Acquisitions; All Clients Onboarded onto...
You ever have that dream where you're being chased and your feet just won't move? You're stuck in the ground and, no matter what you do, you just can't get going. Welcome to the nightmare of micro cap investing.
Despite...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
A brief message for premium subscribers as I think there's a great opportunity here...
TW's Take: Quite an honor for Mark. His “goal of creating a scalable cancer immunotherapy that can be easily delivered to a large number of patients without the need for complex logistics” is underway with INKmune and it’s nice...
TW's Take: Anixa's cancer vaccine continues to demonstrate excellent immune responses and is hopefully partnered off sometime in the next year at a significant premium to the current share price.
SAN JOSE, Calif., March 11, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),...
Last weekend we were in Seattle visiting the kids. It was wet and cold, a very typical Seattle winter weekend, kinda similar to what we had been experiencing in Charlottesville.
Upon arrival back in Virginia on Monday, however, the world...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
This morning enVVeno (NVNO) published the top-line results at the six-month mark of their...
TW's Take: outstanding data makes reimbursement and approval highly likely with significant post-approval uptake. I believe this sets the stage for an acquisition within the next 6-12 months.
97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as...
TW's Take: INAB continues to demonstrate strong science backing their gamma-delta T Cell programs.
New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented.
The platform has...
TW's Take: more solid evidence of the clinical benefits derived from XPro. Really looking forward to seeing phase 2 results around year-end, which could be game-changing for INMB.
Boca Raton, Florida, March 04, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the...
It was a great end to the week as March 1st brought about one of the best days TW has seen. A 6% gain for the portfolio came on a broad based move with every position in the green....
TW's Take: data next week is the missing ingredient to finally send NVNO to a decent valuation. Next gen product positions them for eventual billion dollar or more exit.
$46.4 million cash and investments on hand sufficient to fund...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
A brief update on several stocks, starting with a small trade. As I've been...
The biggest news around TW's universe last week came in a Tuesday morning press release from enVVeno (NVNO).
Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on...
TW's Take: more proof of the importance of MST. We remain more convinced than ever in the eventual commercial success of Atomera.
WHO:
Hideki Takeuchi, Vice President of Engineering of Atomera Incorporated (Nasdaq: ATOM), a semiconductor materials and technology licensing company
WHAT:
In-person presentation of...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Yesterday enVVeno (NVNO) was featured on a call hosted by LifeSci Advisors. A replay...
TW's Take: looking forward to, what I believe will be, outstanding data presented in just over 2 weeks. These results could be the catalyst that propels NVNO towards a greatly improved valuation and likely sparks interest from potential acquirers.
IRVINE,...
On October 28th of last year, I titled my weekly newsletter, In Support of the XBI. In the next two and half months, we saw an epic rally in the index. Epic meaning, the fastest climb of almost 50%...
TW's Take: ADCs are a hot space right now and RADR could be the key to getting Lantern involved rapidly and cost effectively. Exciting work that is pre-clinical but could move quickly into human testing.
Lantern, in collaboration with...
TW's Take: nice endorsement of IN8's therapy. No new news in this article, however.
Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy
NEW YORK, Feb. 14,...
TW's Take: more good news as ALMU executes on their game plan of winning smaller defense and government contracts as they await the potentially much larger industry orders for which they are currently in the sampling process.
New Award Invests...
TW's Take: moving on to the second cohort is a big step forward as the initial cohort completes with zero significant adverse events, something that has plagued other company's solid tumor CAR-T therapies.
Dose escalation for fourth patient follows...
It generally pays to take the opposite side of the group consensus. When the analyst community all forecasts the same outcome, it's safe to say that said outcome is already priced into the market. Taking the other side of...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Trading action in TW's names has been rather slow with microcap stocks in general...
TW's Take: further confirmation that ALMU's technology is well positioned to become a highly disruptive technology for the manufacturing of advanced chips at large volumes.
New Award to Develop Foundry-Compatible Quantum Materials Leveraging Aeluma's Large-Scale Semiconductor Technology
GOLETA, CA / ACCESSWIRE...
TW's Take: we are expecting increased institutional interest in INmune and this conference could help highlight a great program that, with the FDA hold removed, is starting to hit funds' radar screens.
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE)...
TW's Take: This is good news as it firms up the balance sheet as the programs advance towards more milestone and eventual royalty income streams.
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing...
Almost two years ago, I wrote a newsletter titled, Buy the Rumor, Sell the News. The poster child for that article should have been INmune Bio (INMB), a stock that always seems to dislike good news.
This past Tuesday, the...
TW's Take: more positive publicity for SPVNF's solution ahead of the anticipated 800Gbps upgrade cycle.
Demo to Highlight Spectra7’s GC1122 and Teledyne LeCroy’s Xena Z800 Freya 800GE Test System
San Jose, CA – Jan 31, 2024 – (TSXV:SEV) (OTCQB:SPVNF) Spectra7...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
While I'm not actively trading right now, there are a few things going on...
TW's Take: Finally! This doesn't change the phase 2 timeline but sets the stage for phase 3 and also opens the door for more US institutional investors to look at the company. Top line data readout around year-end is...
After staring at various charts, returns and other indicators, I have come to the conclusion that January was just different. Of the stocks I follow, three were down around 20% and three were up double digits...with no rhyme or...
TW's Take: SPVNF continues to position themselves for the next-generation of data center buildouts. Keysight is a solid partner to have in this endeavor.
Demo to Highlight Spectra7’s GC1122 and Keysight’s AresONE-M 800GE Layer 1-3 Test Systems
January 24th, 2024 SAN...
TW's Take: nice recognition at an industry conference demonstrates how exciting this program is and why partners will be looking at TFF very closely as they get to full data release later this Q.
FORT WORTH, Texas, Jan. 24, 2024...
TW's Take: Anixa is slowly developing a portfolio of cancer vaccine assets and this is another step in that direction.
SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention...
TW's Take: finally shipping. Company needs to really beef up their balance sheet before the stock will perform.
PLEASANTON, Calif., Jan. 22, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, announced that its female first wearable, the Evie Ring,...
Winter has come to Virginia this week. It's snowy and cold, with average highs in the 30's. If there's one thing I miss about California, it's the weather in January and February.
Cold weather is a good excuse to hunker...
TW's Take:
DALLAS--(BUSINESS WIRE)-- Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D....
TW's Take: good step towards future orders in what looks to be a burgeoning space.
Spectra7’s New GC1122 Product to be Featured in Several Demos
January 17, 2024 SAN JOSE, CA - (PR NewsWire) – (TSXV:SEV) Spectra7 Microsystems Inc. – (TSXV:SEV)...
TW's Take: a very positive sign, getting initial orders for 800 Gbps. The market is still very early stage and Spectra7 needs more funding, but the opportunity remains exciting.
Major Cable Supplier to Serve Both North America and China...
It's certainly been an interesting start to 2024 with double digit percentage moves in most stocks I follow. The swings have been strong but the direction varied. Half the movers are up and half down with no real rhyme...
TW's Take: we continue to believe that Atomera is on the fast track to royalties with STM and this PR is simply further proof of that eventuality.
LOS GATOS, CA / ACCESSWIRE / January 10, 2024 / Atomera Incorporated (NASDAQ:ATOM), a semiconductor materials and technology...
TW's Take: showing a mortality benefit would be a key differentiator for TFF's programs. While the data set is still too small for this, the ball is certainly moving in the right direction. Mortality benefit equals premium pricing and...
Stocks have started out the new year with a resounding thud. This shouldn't come as a big surprise as the first part of January frequently reverses any late year moves. The market is not cheap, particularly when looking at...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
As we enter the new year, markets are having a rough start. This is...
GOLETA, CA / ACCESSWIRE / January 3, 2024 / Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for LiDAR (light detection and ranging), communication, and sensing, announced today that it will host an exhibitor booth and deliver...
TW's Take: great to see this exciting program entering the clinic. 2024 is a catalyst-filled year for INMB.
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing...
As we wrap up 2023, we had an excellent conclusion to what has been a most challenging year. December was great. The rest of the year, mixed at best. This was true not just for TW but for a...
TW's Take: amazingly large miss either sets the company up for a big 2024 or is an indication that things are going very wrong at SPVNF. The next Q will be very telling.
Successful Testing Event with Leading Datacenter...
With the holiday season now firmly upon us, I'd like to thank every one of TW's subscribers. The last couple years have been challenging in micro-caps but the strong end to 2023 is a welcome gift as we finish...
TW's Take: great quotes in here certainly make it sound like ALMU is on the verge of big things. Looking forward to seeing some big contracts in the near future.
GOLETA, CA / ACCESSWIRE / December 20, 2023 / Aeluma, Inc....
TW's Take: great news as both drugs are exceeding expectations in both efficacy and safety. Number of patients still low but increasing and accelerating the programs is a sign of confidence.
Treatment with TFF VORI resulted in positive treatment...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Late in the day today, I added TFF Pharma (TFFP) to my trading accounts,...
TW's Take: the FDA continues to confound and frustrate INmune as their trial moves forward expeditiously outside the US. Perceptual negative but no real impact on the company.
Enrollment in the Company’s Phase II study using XProTM to treat...
In case you didn't know, the Russell 2000 has just made it's fastest move ever from 52 week lows to 52 week highs. At 48 days, that's the shortest turnaround in the index's history since it was formulated in...
TW's Take: very expected move creates a buying opportunity in front of upcoming data releases.
Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023
FORT WORTH, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP),...
TW's Take: having more quality people joining the board is a good sign heading into important data releases and needed financing. At this price, TFF is in the bargain basement and stands a great chance to rally heading into...
TW's Take: Positive data post yesterday's financing is a great set up for INAB.
Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
When last I posted trading thoughts heading into December, I suggested holding INmune Bio...
TW's Take: solid deal removes the overhang and enables them to get more funding in the future without needing to go to market. Some serious dilution but the stock is now reset and poised to do very well as...
For those who remember Carnac The Magnificent, the answer is "management is highly confident".
Back in the dark ages of life before the internet, Johnny Carson was the king of late night television. One of his signature skits was performing...
TW's Take: excellent data from this novel vaccine program is setting the stage for Anixa to possibly change the whole landscape of cancer vaccine development. Very exciting news for breast cancer patients and investors in ANIX.
Antigen-specific T cell...
The turkey hangover can last several hours or even up to a few days. You have overindulged and need to digest for a while before you'll even consider stepping back up to the buffet. But, if you're anything like...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
In my last update with the year-end game plan, I had laid out the...
TW's Take: good to see this finally coming to market. I await glucose monitoring before I get too excited, however.
PLEASANTON, Calif., Nov. 29, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announces the successful ecommerce launch of...
TW's Take: more exciting data that should perk interest in potential partnering of INB03. Pre-clinical but clinically relevant and potentially very meaningful for patients.
INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant...
TW's Take: INMB is accelerating progress towards full enrollment. Results will be coming in late 2024, which is the key catalyst investors have been awaiting.
Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the...
TW's Take: while early stage, this is based on the same technology as their breast cancer vaccine which is showing great results in phase 1.
SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology...
I hope everyone had a great Thanksgiving. Here in Charlottesville, we celebrated with family and friends. The weather was great, the turkey awesome and the desserts were wonderful. It was all Thanksgiving should be.
Making it easier to enjoy the...
TW's Take: Solid progress with more data expected in December. IN8bio continues to execute but the balance sheet remains an issue and partnering has been elusive to date.
All patients treated with INB-200 who completed mandated doses to date...
As we head into the home stretch for 2023, the markets are back in rally mode. Performing best is the S&P 500 and Nasdaq as larger cap stocks continue to shine. I have been anticipating the end of the...
TW's Take: much needed capital but this company remains very capital constrained.
PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) ("Movano Health" or the "Company"), a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices...
TW's Take: very positive results sets the stage for approval if the efficacy data comes through as expected. We'll see that data in the first half of 2024.
No Deaths or Pulmonary Embolisms Occurring During the 30 Day MAE...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
It came out a week later than expected but Atomera (ATOM) announced the installation...
TW's Take: more jurisdictions approving the AD trial not only bodes well for enrollment but sets the company up for a well received phase 3. Love how the company is very prudent with their cash burn and balance sheet.
...
TW's Take: with the installation of MST in a customer's facility, ATOM has crossed a significant hurdle towards achieving their goals. While we are still over a year from royalty revenue, that light at the end of the tunnel...
This weekend is the Richmond Marathon. Billed as the "friendliest marathon", our daughter is going to be running in her first ever bid to complete the 26.2 miles. It will be a tough slog, but I'm sure she's up...
TW's Take: the promise of TFF's technology continues to be advanced.
Research shows the Company’s Thin Film Freezing can reformulate broad range of monoclonal antibodies in combination with Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System for intranasal delivery
FORT...
TW's Take: INAB's programs are showing great early-stage efficacy. Getting a late-breaking poster slot is proof that more, high-quality data is coming from IN8bio.
Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200
...
TW's Take: data on Nov. 17th will likely be compelling. INAB continues to keep patients alive and progression free far longer than expected.
Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta...
This past week saw, to everyone investors' great relief, a much needed bounce in the markets. This was particularly true for smaller cap stocks and biotech in particular with the XBI rallying over 12% off intraday lows set on...
TW's Take: while early stage, allogeneic gamma-delta T-cells would be a very big deal. INAB continues to execute on their vision.
This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion...
TW's Take: more positive data. INAB is executing and patients continue to do very well on their drugs.
New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on...
TW's Take: as this trial is now in its second cohort, good to see it getting some industry recognition.
Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial
SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or...
TW's Take: good news as they are working towards a solution for blood pressure in their Evie Ring, but still quite a ways off.
Leveraging the Company's 4 x 6.7 mm System-on-a-Chip (SoC), the clinical study results are a...
TW's Take: the INKmune program is getting up to speed with patient enrollment now meeting or beating expectations. Patentability is key for the long-term in these cells lines and this opinion is very favorable for INmune.
INmune Bio receives...
TW's Take: more pre-clinical support for INB03. This program is a potential partnering opportunity or will be taken into phase 2 once the AD program reads out next year. Either way, lots of interesting upside from a program that...
One of my mentors loved to say, "bull markets attract thieves." The point being that, any industry that was garnering investment capital would come to the attention of financiers, who would enter the industry in an attempt to gain...
TW's Take: we continue to be in a holding pattern as we await the expected ramp up in business driven by the pending transition to 800G. Will S7 be a big piece of this puzzle? We'll find out in...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
As we head into the end of the year, markets are making it very...
SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory...
Last week, when discussing supply and demand, I wrote that "the landscape is tilted towards lower stock prices." That was certainly the case the last five days as the market took a beating. Suffering more than the average bear...
TW's Take: this is clear evidence that INmune is on the right path to an effective treatment for Alzheimer's. Improvement in the pathologies at the earliest stages of the disease (as opposed to later like the anti-amyloid treatments) is...
This weekend's newsletter comes to you from Napa Valley, CA, where Mrs. Carlson and I are attending a wedding. Napa is not a bad place to get married and it's nice to be back in CA for a few...
TW's Take: Great news as this exciting therapy advances towards larger doses and, hopefully, efficacy.
- With no dose-limiting toxicities observed, treatment of second dose cohort to begin
SAN JOSE, Calif., Oct. 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),...
TW's Take: Solid progress from INAB in this very promising therapy.
Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM).
Enrollment completed in the dose escalation phase...
I have been espousing several themes in this newsletter for quite a while now. These themes are the big picture drivers that impact our ability to make money in the market. This past week was an overall great example...
enVVeno (NVNO) put out a hat trick of press releases today. The news ranged from getting $28 million in a private placement to fundamental updates on both their products. On the surface it all seemed great and the stock...
TW's Take: this product has multi-billion dollar potential and it's great to see the timeline moved up by 6 months. Non-surgical implantation is a game-changer that greatly expands the market.
– enVVe development cycle to be reduced by 6 months
–...
TW's Take: company is exceeding expectations on all fronts. Great news.
– 18 VenoValve patients enrolled over the final two months of the study
– Surge in VenoValve demand exceeded the enrollment limit
– Topline safety and efficacy readout and PMA eligibility...
TW's Take: very positive getting top-notch investors to pay above the market. Financing risk now completely eliminated and the company is exceeding timelines on both products as announced in other press releases today. I remain very bullish on NVNO.
Up...
TW's Take: early stage but an exciting program based on work from the inventor of their breast cancer vaccine, which is going very well.
SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company...
In college I played second row on the rugby team. Our squad was a solid group of ruggers with a core of both international players, who had grown up with the sport, and domestic athletes who thoroughly enjoyed the...
TW's Take: patients continue to see progression-free survival far in excess of expectations. The presentation will continue to highlight this fact. INAB is executing on their business.
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a...
TW's Take: All systems firing for INAB as they look to get more interest in their programs which are doing well despite the share price.
Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
A couple months ago I loaded up on enVVeno (NVNO) on the basis that...
TW's Take: LTRN is starved for clinical data and this program could be a driver of significant value over the coming year as LP-184 appears to be highly potent. Results could start coming in during Q4.
LP-184 is being...
Last week the average TW stock was down 2.8%, roughly in line with (or slightly better than) the overall market. As a group, the performance was rather muted versus the indexes. However, the individual stock performance reflected anything but...
TW's Take: positive execution on their business strategy which positions them even better for potential partnering activity.
~ Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and...
TW's Take: this is a very strong group of individuals. Hopefully the establishment of this board leads to a meaningful partnership on one or more of their programs in the not too distant future.
SAN JOSE, Calif., Sept. 19, 2023 /PRNewswire/ -- Anixa...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced that the United...
This week the heat finally turned off here in Charlottesville with temperatures coming down from the 90's to a more reasonable level. Despite school having been back in session for a few weeks, it seems that summer is finally...
TW's Take: needed capital as we await a contract from a North American data center operator. Fingers crossed it's soon, but delays are weighing here.
Toronto, ON – September 13, 2023 – (TSXV:SEV) (OTCQB:SPVNF) Spectra7 Microsystems Inc. (“Spectra7” or the...
This past week was dreadfully dull. Volume across the board was anemic and the tone from traders was muted. August may in fact be over but it appears no one told that to the market.
Back in July I wrote...
TW's Take: good news as this approval should not only accelerate enrollment but is a positive sign as we await expected EU and FDA approvals.
The authorization provides approval for the Company to expand the ongoing Phase 2 trial of XPro™ in patients...
Sadly, the dog days of summer are over. September is here and investment bankers, traders and most of Europe will be returning to work. The quiet market of August is hopefully a thing of the past and I'm hopeful...
TW's Take: enrollment is finally picking up and the therapy has shown an excellent safety profile and some moderate efficacy at the initial, sub-therapeutic levels. Looking forward to getting data later this year and hopeful that enrollment continues to...
TW's Take: RADR is a powerful tool. How Lantern will monetize this remains the biggest question mark around the product. Eventually the value of RADR will be demonstrated to the market.
Expansion of RADR® platform adds new AI capabilities for...
"The single most important thing for me in the stock market
is to know what you own." ~ Peter Lynch
It's tough out there. Markets are trading down on higher rates, volumes are light and apathy seems to rule the day....
TW's Take: the story inches closer to success. Spectra7 is well positioned for the upgrade cycle that looks likely to commence around YE 2023.
Record H1 2023 Revenue and Gross Margin at 63%
SAN JOSE, Calif., Aug. 22, 2023 /PRNewswire/ -- (TSXV:SEV) (OTCQB:SPVNF)...
Inflation data keeps coming down, analysts continue to see an end to rate increases, yet markets are weak. What gives? My opinion, it all comes down to what Fitch warned about recently; the large and increasing debt level of...
TW's Take: much needed capital provides a runway through data in Q4. Insider participation in the financing is a positive and it's now time for TFF's management to execute on these trials and generate some value for shareholders.
Announced...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Last night TFF Pharma (TFFP) raised $5 million at $0.25. With the expected over-allotment,...
TW's Take: more scientific validation for this unique therapy provides further evidence of a potentially blockbuster solid-tumor cancer platform.
SAN JOSE, Calif., Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and...
The big news this past week was INmune (INMB)'s earnings release and conference call. Or was it? The stock was down over 10% on Tuesday, following the shareholder update, but finished the week down a whopping 3.4% which is...
TW's Take:
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell therapies
The new site supports IN8bio’s commitment to develop a strong biotechnology presence in the Birmingham region
NEW...
The women-led board will leverage their medical and scientific expertise to enhance Evie's product roadmap and provide trusted content
PLEASANTON, Calif., Aug. 10, 2023 /PRNewswire/ -- Today, Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices...
TW's Take: my thinking behind this "news story" is that management is frustrated by the lack of value being assigned to the company in light of the outstanding data from this program.
SAN JOSE, CA / ACCESSWIRE / August 10,...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
In my last update, I detailed how I thought enVVeno (NVNO) was likely to...
TW's Take: this trial will have meaningful results in December which could be the closest game-changing event for Anixa. Very exciting opportunity that the market is dramatically under-appreciating.
SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:...
TFF Pharma has been a terrible stock. It has gone straight down for longer than I care to remember. I admit to having been wrong on this one so far.
At the time when I first bought the stock the...
TW's Take: yet another sign that the product works and is uniquely improved over the currently approved version of the drug.
Voriconazole Inhalation Powder (TFF VORI) is an investigational, inhaled formulation of voriconazole developed using TFF Pharmaceuticals Thin Film...
When explanations make no senseWhen every answer's wrongYou're fighting with lost confidenceAll expectations gone
If those words from Swing Out Sister's song "Breakout" don't sum up the state of investing in biotech these days, nothing does. Overall, markets are strong...
TW's Take: this program has great potential and is overlooked by the market, but is very early stage so not really impactful to today's stock price.
SAN JOSE, Calif., July 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a...
The Holy Grail is a treasure that serves as an important motif in literature. With mystical powers, the belief is that drinking from this chalice can provide eternal youth and infinite sustenance. In short, everything you could wish for.
In...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Last week I was buying enVVeno (NVNO) as the stock had been hit on...
TW's Take: exciting times ahead as the data center market is moving towards a future in which Spectra7 sits in the sweet spot for connectivity.
San Jose, CA – July 18, 2023 – (TSXV:SEV) (OTCQB:SPVNF) Spectra7 Microsystems Inc. (“Spectra7” or...
Now that we've officially declared "Global Warming" as misleading, having rebranded it to "Climate Change", the world seems to be heating up faster than ever. Both land and ocean temperatures are hitting record highs and the only thing rising...
TW's Take: we continue to believe this device is going to succeed and be a big deal for NVNO.
IRVINE, CA / July 14, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
enVVeno (NVNO) got hit this week after their CEO spoke at a conference. His...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
This week has seen three press releases out of INmune Bio (INMB), including data...
TW's Take: as this keynote address demonstrates, INmune is the leader in using biomarkers of inflammation to demonstrate cognitive decline. Removing soluble TNF with XPro1595 has the potential to be a part of anti-aging therapies, a field that is...
TW's Take: the company continues to build their patent portfolio while we await more data from the program. Hopefully we will learn more in the coming weeks.
Technology currently being evaluated for the treatment of ovarian cancer in Phase...
TW's Take: very positive data that should open some eyes at AAIC next week. INmune continues to lead the field in developing new biomarkers for AD; biomarkers on which XPro has a very positive clinical benefit.
Analysis of MRI scans...
TW's Take: more highly supportive evidence of the beneficial effects of neutralizing soluble TNF. Adds to the growing body of evidence supporting XPro.
Neutralizing soluble TNF with XPro™ promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses
Boca...
TW's Take: this is very positive as it will lead to more industry recognition and really accelerate growth.
THE COLONY, Texas, July 10, 2023 (GLOBE NEWSWIRE) -- Quest Resource Holding Corporation (NASDAQ: QRHC) ("Quest"), a national leader in environmental waste and recycling services,...
Holiday weeks are generally the slowest times in the market both in terms of activity and also news flow. With the 4th of July happening mid-week this year, that trend is more pronounced than normal. Yet, there is still...
TW's Take: trial progressing well, results will come early next year which is a modest delay from the original timeline but expected in any trial run during Covid. Overall, very excited for the future here.
57 patients enrolled to...
As I sit here today in Massachusetts, socked in by a combination of Atlantic fog and Canadian smoke, it's tough to imagine a beautiful fireworks display in three days. Yet, that is the hope as the Boston Pops will...
TW's Take: more confirmation of the potential of thin-film-freezing in this excellent endorsement from NIH. We continue to await data from their lead programs later this year.
National Institute of Health/National Institute of Allergy and Infectious Disease Direct to...
TW's Take: Lantern's early stage data is compelling and sets the table for these programs, which are nicely funded already, through key milestones.
Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of...
This week I'm writing about a topic I like to refer to as "Free Call Options". Honestly, the name is a little misleading but the concept works like this; There are stocks whose current valuation is based solely on...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Recently a new subscriber asked me to give some guidance as to the prices...
Last week I wrote extensively about INmune Bio (INMB), my favorite stock idea heading into the second half of 2023. The numerous catalysts and significant upside to the stock, combined with increasing clinical execution, make it an intriguing stock...
TW's Take: needed breathing room in front of some major upcoming catalysts.
PLEASANTON, Calif., June 13, 2023 -- Movano Health (Nasdaq: MOVE) ("Movano Health" or the "Company"), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
A couple stocks to discuss with premium subscribers. I'm going to continue to update...
TW's Take: an important step, LP-184 is a potential blockbuster and this program should have results prior to the end of 2023. Lantern, with a ton of cash, is looking increasingly attractive.
LP-184 is a novel, synthetically-lethal, small molecule...
When I initially got involved with INmune Bio (INMB), one of the first pieces I published on the company was titled, "INmune’s Efforts in Alzheimer’s…Low Risk to Phase 1b Success???" At that time, it was quite apparent to anyone...
TW's Take: Lantern's A.I. database for cancer therapeutic development is the largest in the world and positions them to be a leader in ADC development, a booming class of drugs.
Lantern will leverage its proprietary AI platform, RADR®, to...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I wanted to put out a brief note for premium subscribers in light of...
TW's Take: 100% exceeding PFS with dose response and minimal toxicity is all anyone could ask for from this program. Next up for INAB is a partnership, which would be a major catalyst.
100% of treated patients (n=8) to...
Writing this newsletter in on May 31st as I'm heading out to another graduation, this time in South Carolina. I've driven through the state, on I-95, several times but have never spent any time there. Hence, I'm looking forward...
One of my readers has been leaving me a lot of messages about Anixa (ANIX) of late. The general gist of his communication is that the stock isn't performing. He's upset, which I totally get. It's no fun watching...
TW's Take: INKmune continues to have outstanding data that makes it potentially the market leader in NK cell therapies. The data being presented looks certain to open eyes in regards to how INKmune stacks up to the competition.
Presidential...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I wanted to drop a quick note with my updated thinking on a few...
TW's Take: nice to see this program gaining some momentum. Due to changes in their recruitment process, expect to see enrollment accelerate and results from patients should start coming out fairly consistently going forward. Success in a solid tumor...
Last week I took off from publishing as I was meant to be skiing out west. Well, not exactly skiing in the traditional sense of having nice rides up the mountain and smooth sailing down groomed trails. The version...
TW's Take: INAB is looking to partner their programs and the strong results in conjunction with TMZ, the standard of care in many cases, should provide strong impetus to bring partners to the table.
Preclinical results showcase the potential...
TW's Take: SPVNF is poised to grow rapidly if they can execute on landing a large piece of the US data center market's upgrade to 800G. The second half could be very interesting for S7!
New 800G/1.6TB Datacenter Products...
TW's Take: nice to see that the technology continues to impress enough to sign a CRADA but we await the real news of phase 2 results from VORI and TAC.
FORT WORTH, Texas, — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the...
TW's Take: More positive data that pulls in another possible avenue for partnering.
Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of these technologies outside...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I have continued adding to my IN8bio (INAB) position. There are only a handful...
TW's Take: nice to see that this program continues to advance. TFF has been quiet for a while. Expect to see some more news on their internal programs here in Q2, which could be a nice catalyst.
FORT WORTH, Texas,...
My thesis heading into 2023 was to expect a trader's market. This looked to be a year filled with catalyst driven moves and high volatility, but lacking a definitive trend and, as was the case for the prior 18...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Last night Atomera (ATOM) announced the inking of a commercial license with ST Micro....
TW's Take: very exciting news for ATOM as they are closer than ever to getting into production. The finish line is coming into sight for these guys. And, it's a massive win if/when they cross over it.
LOS GATOS, Calif.--(BUSINESS...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I have bought shares of IN8bio (INAB) in my trading account. This stock is...
TW's Take: obviously good data with an oral presentation, INAB continues to kick butt in all their clinical programs.
NEW YORK, (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies,...
TW's Take: solid results but it's all about their guidance for data center wins in the 2nd half of 2023. If this comes to fruition, the stock should do very well.
SAN JOSE, Calif., -- (TSXV:SEV) (OTCQB:SPVNF) Spectra7 Microsystems Inc. ("Spectra7"...
TW's Take: simply outstanding data from this program. While the balance sheet remains an issue, the value being created here is substantial and we could be in for a long run in the stock once they get more cash...
A few weeks back I wrote about catalysts that weren't going to help your stocks. It was meant to be a little tongue in cheek but it's truly that kind of market. In case you require further proof of...
TW's Take: this trial demonstrates that inhibiting TNF arrests the development of amyloid pathology in TBI patients, but also gives hope that this works across al patients, which would be a huge step towards demonstrating that TNF is indeed...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Yesterday Anixa (ANIX) traded down 25% on the back of a data release from...
TW's Take: very positive data from this program. Market continues to under-appreciate this company and its data.
SAN JOSE, Calif. -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic...
Tailwinds Research (TW) – Your presentation at AACR looked impressive, but how should investors interpret the data?
Dr. Amit Kumar (AK) – In this first phase of the trial, we wanted to confirm that it was safe, that we could...
TW's Take: more solid progress from INAB. The disconnect between the valuation and the success the science demonstrates continues to grow.
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing...
This past week saw very big gains in my two largest holdings, with Anixa (ANIX) trading up 34% and INmune Bio (INMB) closing up almost 27%. I'll be very honest when I say that it feels quite wonderful to...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the...
TW's Take: more positive news from INAB which appears to be very successful with all their programs to date.
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta...
TW's Take: INB03 has been shown to have a very positive impact in reducing the tumor micro-environment, which enables other therapeutics to perform better. This is further proof of this impact and helps position INB03 for partnering.
Boca Raton, April...
Not to spend too much time looking in the rear view mirror, but a note I got from BTIG this past week did a nice job of summarizing the pain we have been facing in our biotech names.
How Long...
TW's Take: good progress on what looks like a very promising treatment in solid tumors. Nice to see the latest patient in the AML trial is doing well and showing memory-like NK cells. INKmune has a lot of potential...
If you like roller coasters, investing in TW's universe certainly gave you thrills in the first Q. Our portfolio was up 15% in January, topped out around up 20% in February but closed the month unchanged, and took it...
TW's Take: the prior trials of LP-300 showed a dramatic improvement in this smaller subsection of the population, making this trial quite likely to show clinical benefit.
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its...
TW's Take: looking forward to seeing the results of this breakthrough vaccine which should be a major catalyst for Anixa.
SAN JOSE, Calif., March 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
When I moved to San Francisco in 1989, Herb Caen was a renowned columnist for the San Francisco Chronicle. His was an unabashed lover of the city he called Baghdad by the Bay and his articles were a treasure...
TW's Take: we greatly look forward to the results from the glucose monitoring tests that are due to start "imminently".
PLEASANTON, Calif., March 20, 2023 /PRNewswire/ -- Today, Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer...
How do you know when you're in a bear market? The simplest answer is this, All News Is Bad. When a company puts out a press release describing an accomplishment that simply becomes a generator of trading activity and...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I have repurchased Atomera (ATOM) across all my accounts. I have also bought it...
TW's Take: yet more very positive data from INAB. As more patients get dosed in trials, this is setting up to be a very successful platform opportunity. Expect to see a partnership sometime in the near future.
NEW YORK, March...
TW's Take: the key line from this PR is that the SoC is being tested on patients in this current month of March. Those results will be pivotal for the company as glucose monitoring is the key to a...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
In my trading accounts, I had bought a position in Spectra7 (SPVNF) in December...
TW's Take: there is definite interest in S7's technology in the next generation of data center designs. We look forward to seeing this translate into increased orders.
March 13, 2023 SAN JOSE, CA - (PR NewsWire) – (TSXV:SEV) Spectra7 Microsystems Inc....
Funding just got tougher.
My frequent description of TW's universe is that of "public venture capital". Our stocks share many of similarities with those companies funded by the VC community, being small, high growth and cash burning. With the market's...
TW's Take: This is very positive as it removes the financing overhang and positions the company for a high-growth phase that it anticipates entering later this year.
TORONTO, ON, March 10, 2023 -- (TSXV: SEV) (OTCQB: SPVNF) Spectra7 Microsystems Inc....
TW's Take: excited for this call as I have long felt that Lantern's LP-184 has billion dollar potential.
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML)...
TW's Take: Movano is positioning themselves well in this market with potentially best in class performance and FDA approval driving adoption.
PLEASANTON, Calif., March 7, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer...
This past week was a surprisingly great week in TW's universe. I say surprisingly as, after watching INmune Bio (INMB) take a morning bath on Friday, the number of comments I received lamenting the portfolio's recent performance made it...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Yesterday INmune Bio (INMB) reported earnings and hosted an investor update call. Not much...
TW's Take: Lantern is positioning themselves for success in clinical trials. Once they get rolling, the market should start to pay attention.
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI)...
TW's Take: this is a positive step but we would like to see many more of these, creating a portfolio of partnering opportunities around RADR, in order to get really excited.
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical...
TW's Take: all systems go for the vaccine as we await key data in April that should be the catalyst for shares of ANIX.
SAN JOSE, Calif., Feb. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the...
In the last two newsletters, I have been saying that the markets looked ready to move lower. More exactly, two weeks ago I said the following...
Baton down the hatches and keep some gunpowder in reserve. I think the next...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
This morning I've been adding to TFF Pharma (TFFP) across all my accounts.
As I...
TW's Take: Exciting data that should help drive important partnering conversations for INAB with potential large pharma partners.
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, announced...
TW's Take: an impressive board of individuals who likely believe in the future success of this vaccine if they are lending their name to the program.
SAN JOSE, Calif., Feb. 21, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Having just written my weekly newsletter, I wanted to put out a note to...
A lot of market forecasters have been declaring this past week to have seen the end of the recent bull market. Having missed the upward movement as a group, they are now doubling down on their bearish forecasts. And,...
TW's Take: more positive progress on this innovative platform. Exactly how they monetize this data is still the question in my mind, but I'm certain that it's coming at some point.
DALLAS -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical...
TW's Take: positive development as we wait to see if Spectra7 can earn design wins into the large North American market. If they do start booking wins, stock should be off to the races.
San Jose, CA – February 14,...
After a great start to the year, this last week the stock market reminded investors not to get too complacent. As I've said several times over the past few newsletters, the market was pricing in a Goldilocks Scenario. When...
TW's Take: the 2nd half of 2023 looks to be make or break for investors in SPVNF as the company is positioning themselves for big wins. If they come through, the stock should be a big performer.
Santa Clara, CA...
TW's Take: Looking forward to getting updates on their in-house programs. The stock is very inexpensive but investors need to gain some degree of comfort in the progress of the trials.
FORT WORTH, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) —...
TW's Take: INmune is a very good steward of investor capital, as this demonstrates. This adds an additional quarter of funding to INMB in a completely non-dilutive manner.
BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Yesterday ParkerVision (PRKR) announced a settlement with Intel. While the settlement is a "win"...
Last year I wrote an article comparing playing backgammon to investing. The key to success in backgammon is focusing on the doubling cube. Knowing when the odds are in your favor and stepping into a bet in a big...
TW's Take: Spectra7 is positioning themselves to try to enter the US data center market. If they can get design wins in 56 or 112 gbps PAM4 architecture, the stock will likely soar.
Santa Clara, CA – February 1, 2023...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
This week, in my trading accounts (not my long-term accounts), I have sold out...
TW's Take: positive to get some financing done which should allow the company to achieve key milestones without additional financing. The biggest risk to this story was and remains financing as their burn rate is high. However, they should...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
This morning INmune Bio (INMB) put out a press release discussing a program being...
TW's Take: exciting news as the "wonder drug" that is XPro demonstrates exciting data in yet another major, untreated disease.
Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...
In 2022, interest rates killed micro-cap. This year, with increased expectations of a recession and an associated end of rate increases, the smaller stocks are back in play.
This is increasingly apparent within the TW universe where, despite the market...
TW's Take: Glad to see that the company will be approaching, if not achieving, EBITDA positive operations very soon. Stabilizing the cash flows and balance sheet positions the company well for what we believe will be an eventual acquisition.
SAN...
TW's Take: our view on NVNO remains that the product will gain approval and substantial sales, but likely remains off investors' radar screens until closer to approval. This PR is more evidence that the company is headed in the...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I had a couple of interesting conversations over the last week that are impacting...
TW's Take: continued execution as they move this incredibly promising drug into human trials sometime in the not too distant future. LTRN still trading for close to cash value.
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical...
It has been a great start to 2023, particularly for smaller, growth stocks. The most likely explanation for this is investor expectations regarding inflation and future interest rates. While FED officials keep harping on further rate increases, the bond...
Entering 2023, I'm fairly confident that everyone who subscribes to TW's service knows my thoughts on the overall market. In a nutshell, I believe inflation is going to be stickier than we would like, a recession is quite likely...
TW's Take: when SPVNF finally starts ramping sales of active copper cables into data centers, the stock should launch.
LAS VEGAS, Jan. 5, 2023 /PRNewswire/ -- (TSXV: SEV) (OTCQB: SPVNF) Spectra7 Microsystems Inc. ("Spectra7" or the "Company"), a leading provider of high-performance...
TW's Take: this is a great step, bringing in house the expertise needed to take products through clinical development and commercialization or partnering.
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical...
This past week, thanks to a big move on Friday, saw the markets start the new year on a positive note. Investors increasingly believe that the "Goldilocks Scenario" is likely to play out. For this to happen, inflation has...
TW's Take: Gamma-Delta T-Cells is a very hot space and IN8bio is proving to be a leader here. The stock is dramatically undervalued relative to competitors with better data. The potential here is very, very large if they continue...
TW's Take: expecting good news from their GBM program this coming week before they start presenting to investors in San Francisco.
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing...
In the hills just west of Charlottesville lies the Crozet Tunnel. Built in the mid 1800's, it was a major supply route in the Civil War. Considered an amazing feat of engineering, the elliptical design of the tunnel allowed...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Year end tends to be a very volatile time of the year. Portfolio managers...
TW's Take: if they can get FDA approved, will be a key differentiation versus the competition. Movano is significantly undervalued relative to peers and we should start to see that change as they roll the product out.
PLEASANTON, Calif., Dec. 28,...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I have initiated a position in IN8BIO (INAB) in my long-term and managed accounts....
in 2022 I will not be filling your inbox on Christmas Day, instead taking a week off from publishing. This will give everyone a chance to enjoy the holiday without me delivering more coal to readers. A good thing...
TW's Take: The data the company has generated is strong enough that one can see them having an FDA approved device, which would be a big differentiator for Movano versus the competition.
PLEASANTON, Calif., Dec. 14, 2022 -- Movano Health (NASDAQ:MOVE), a purpose-driven...
TW's Take: Movano is moving forward on their commercial launch, expected to be formally introduced at CES in January.
WINSTON-SALEM, N.C. and PLEASANTON, Calif., Dec. 13, 2022 -- Today, Novant Health, a not-for-profit integrated system of medical centers with more than 1,800 physicians...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced...
TW's Take: more exciting but only pre-clinical data for Lantern. The company is positioning itself for an exciting 2023 as they roll into clinical trials. The valuation here, trading for around cash, remains insanely cheap.
DALLAS -- Lantern Pharma Inc....
Earnings and Interest Rates drive everything in the stock market. At the core of investing, this is all you need to know. When earnings are increasing, stocks go higher. When interest rates are going down, stocks go higher. When...
TW's Take: nice to see that phase 1a is on track to present data in Q2 of next year. This will be a significant milestone for the stock and potentially for women everywhere.
SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences,...
TW's Take: positive news but, until enrollment picks up or the solid-tumor trial in the US starts, this program is not going to get any respect from the market.
Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:...
TW's Take: excellent pre-clinical data sets the stage for the long-term success of INB-03. Another reason that, once the FDA hold is removed, this stock is set to soar.
Boca Raton, Florida, Dec. 06, 2022 -- INmune Bio, Inc. (NASDAQ: INMB)...
TW's Take: this has been a long time coming with the company's outstanding technology never seeming to get out of the starting gate under Glenn's leadership. Hopefully the promise of thin-film-freezing will become a reality sometime in the near...
This past week I had a rather interesting conversation with a very shrewd investor who has done quite well over the course of his career. He also happens to be on the board of one of my companies and...
TW's Take: solid growth from AR/VR lines offset the continued disappointment from the data center business. Spectra7 is a "show me" stock with a very low valuation and a lot of upside if/when they start executing on all product...
TW's Take: this PR sums up quite succinctly what makes INmune different from other companies targeting Alzheimer's Disease. Once the FDA approves the trial here in the US, we believe that INMB will be the subject of significant investor...
One of the strangest Thanksgiving Day traditions in this country is the annual pardoning of the Turkeys. This tradition, started by John F. Kennedy in 1963, in its current form, enables two large birds to escape the butcher's block....
TW's Take: more outstanding pre-clinical data. Lantern will take LP-184 into phase 1 trials in 2023, which should be very interesting for investors.
DALLAS -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial...
As a kid, I grew up in the Boston area. Which makes me a life-long Red Sox fan. Since 2003, this has been a good thing but believe me when I say, I lived a tormented childhood with every...
TW's Take: removing the financing overhang is great news for investors. The company now has a runway to reach key milestones over the next few quarters without staring at an impending offering. I suspect we see a nice rally...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
This afternoon, TFF Pharma ($TFFP) announced a financing. Due to participation in this transaction,...
TW's Take: this is excellent data. Showing the long-term benefits is going to be key to marketing the product and getting potential partners excited. The data here is consistent and outstanding, overcoming the fact that it's only a small...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Quest Resource Holding ($QRHC) reported earnings on Monday. Due to a one-time non-cash charge...
TW's Take: good progress but really need to get the FDA's approval to dramatically move the needle on enrollment. Frustrating but will come.
BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology...
Wil the last one in the Crypto room please turn out the lights?
The last time I wrote about Crypto was in August when I had this to say, "I think Bitcoin is about to make another downward move on...
TW's Take: this trial continues to run ahead of expectations and increased awareness will position ANIX for a strong move into data in 2023.
SAN JOSE, Calif., Nov. 8, 2022 -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment...
TW's Take: enVVeno is executing flawlessly in this trial, setting the company up as a great risk/reward when you look out a little over a year when top-line data will be released.
IRVINE, CA / November 7, 2022 / enVVeno Medical...
As a kid did you eat your vegetables first or save them for last, hoping your parents wouldn't notice? I always ate them first with a fear of missing out on dessert if I didn't eat them. So, in...
TW's Take: this bodes very well for the upcoming Intel trial, which takes place in three months. Establishing precedent of companies licensing their patents is a big positive to put in front of a jury.
JACKSONVILLE, FL / ACCESSWIRE /...
TW's Take: another early stage partnership that positions TFF well for next-gen vaccines but does little to overcome the concerns around the company's finances. TFF is as exciting as ever, long-term, but needs to show a clear path to...
Yesterday afternoon TFF Pharma ($TFFP) announced delays in data from both their VORI and TAC phase 2 studies. In previous guidance, given by the CEO around three weeks ago, investors were told interim data from these programs would be...
TW's Take: tough to understate just how disappointing these delays are to investors. Management's guidance on the timing of these programs has been flat-out wrong continually.
FORT WORTH, Texas, Nov. 01, 2022 — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage...
TW's Take: positive results that are meaningful to the big picture here but will be ignored in light of the continual delays in this trial that were also announced this afternoon.
FORT WORTH, Texas, Nov. 01, 2022 — TFF Pharmaceuticals, Inc. (NASDAQ:...
TW's Take: not sure why this senior litigator would join the board unless he felt that PRKR has a compelling case. Interesting development to say the least.
JACKSONVILLE, FL / ACCESSWIRE / October 31, 2022 / ParkerVision, Inc. (OTCQB:PRKR) announced today...
TW's Take: the scientific community is getting increasingly excited about Anixa's CAR-T treatment as demonstrated by its upcoming presentations at important conferences.
SAN JOSE, Calif., Oct. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention...
This past week Mrs. Carlson and I got the opportunity to tour the West Wing of the White House. A really unique and exciting experience, we got to walk through the working offices in the after hours and, making...
TW's Take: very positive news as Raouf is an experienced veteran who has had liquidity events in the past and knows how to position SPVNF for a profitable exit sometime in the next couple years.
October 25th, 2022 SAN JOSE, CA...
TW's Take: the company continues to make excellent progress. Data next year will be the game-changing event for the stock.
IRVINE, CA / October 27, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of...
TW's Take: Anixa's Breast Cancer Vaccine program moving into phase 1b this quickly is definitive proof that they have seen excellent results so far. Now they move into healthy volunteers who are, due to genetically high risk of TNBC,...
Everyone has heard the saying, "can't see the forest for the trees." Roughly translated this speaks to getting so caught up in the minutiae that you miss the big picture. Heading out to go surfing on some really good...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the United...
TW's Take: very positive news, albeit pre-clinical. This program is set to hit US trials in 2023, which would be a big deal for INmune when that happens.
BOCA RATON, Fla, Oct. 19, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc....
